Market Cap
$9.1B
PTGX
Protagonist Therapeutics, Inc
$140.28 ▲ +0.78%
Prev close $139.19Market cap$9.1B
ConsensusStrong Buy
12-mo target$174.69 (+24.5%)
▲ Bullish
Analyst conviction 10/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)33 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PTGX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (95%)
Inst. Holders
50 funds
Inst. Value
$7.6B
Inst. Activity
33 buys / 16 sells
Insider Activity
$0.00 buy / $71.1M sell
Insider Net $
-$71.1M
Social Sentiment
50° Neutral
SEC Reports
8
Price chart 30d -4.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 10, 2026 Insider
PATEL DINESH V PH D acquired via exercise 7,278 shares
President and CEO @ $21.58 ($157.1K)
Sep 10, 2026 Insider
PATEL DINESH V PH D sold 7,278 shares
President and CEO @ $144.10 ($1.0M)
Sep 9, 2026 Insider
PATEL DINESH V PH D acquired via exercise 63,548 shares
President and CEO @ $21.58 ($1.4M)
Sep 9, 2026 ftd
Aug 11, 2026 SEC FTD: PTGX — 28,995 shares ($4.2M) failed to deliver
Settlement: 20260909, Price: $145.94, FTD Value: $4,231,530.3, PROTAGONIST THERAPEUTICS INC C
CEO Dinesh Patel filed a Form 144 notice of intent to sell 225,000 shares of Protagonist Therapeutics (PTGX) through J.P
144 — Impact 5/10
Jun 30, 2026 Inst.
UBS Group AG — TRIM
3,399,221 shares ($416.7M)
Jun 30, 2026 Inst.
Jun 19, 2026 SEC Alyeska Investment Group, L.P. — ADD
889,298 shares ($109.0M)
Protagonist Therapeutics held its 2026 Annual Meeting on June 17, 2026, where stockholders approved the new 2026 Equity
8-K — Impact 3/10
Analyst ratings buy % +6.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
95% rate it Buy or better · 20 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 1, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Sep 1, 2026 | BMO Capital | MAINTAIN | Outperform | 53% |
| Aug 31, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Aug 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 17, 2026 | BMO Capital | MAINTAIN | Outperform | 53% |
| Aug 10, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 10, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Aug 10, 2026 | Goldman Sachs | UPGRADE | Buy | 54% |
| Aug 6, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Aug 6, 2026 | Barclays | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 12 | 1 | 0 | 0 | 95% | |
| Aug 1, 2026 | 7 | 11 | 2 | 0 | 0 | 90% | |
| Jul 1, 2026 | 7 | 11 | 2 | 0 | 0 | 90% | |
| Jun 1, 2026 | 7 | 11 | 2 | 0 | 0 | 90% | |
| May 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Feb 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% |
Price targets
Where 13 covering analysts think PTGX trades over the next 12 months.
$174.69 +24.5% upside Strong Buy
Current$140.28 Low$149.00 Median$171.00 High$225.00 13 analysts
$149.00$225.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 1 bullish, 2 bearish, 2 mixed, 3 neutral · avg impact 5.0/10.
BEARISH1445/10
CEO Dinesh Patel filed a Form 144 notice of intent to sell 225,000 shares of Protagonist Therapeutic
Aug 11, 2026
NEUTRAL8-K3/10
Protagonist Therapeutics held its 2026 Annual Meeting on June 17, 2026, where stockholders approved
Jun 19, 2026
MIXEDINST-CLUSTER5/10
In Q3 2024, 15 institutions accumulated $54.4M in PTGX (net +$43.4M) while 13 sellers reduced holdin
Jun 12, 2026
NEUTRALCLUSTER4/10
Protagonist Therapeutics CEO Dinesh Patel sold $7.5M worth of stock on May 12, 2026, following a $60
May 15, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 9, 2026
ftd
FTD: PTGX — 28,995 shares ($4.2M) failed to deliver
Settlement: 20260909, Price: $145.94, FTD Value: $4,231,530.3, PROTAGONIST THERAPEUTICS INC C
Sep 3, 2026
ftd
FTD: PTGX — 47,443 shares ($6.9M) failed to deliver
Settlement: 20260903, Price: $146.08, FTD Value: $6,930,473.44, PROTAGONIST THERAPEUTICS INC C
Aug 4, 2026
earnings_calendar
PTGX Q2 2026 Earnings After Market Close — 2026-08-04
Jul 7, 2026
short_volume
Short Volume: PTGX — 89.1% short (0.5M / 0.6M)
Short: 514,472 | Exempt: 6,018 | TRF Vol: 577,435 | Short Ratio: 89.1% | Off-exchange volume (dark pool + OTC)
Jun 29, 2026
ftd
FTD: PTGX — 56,454 shares ($6.9M) failed to deliver
Settlement: 20260629, Price: $121.88, FTD Value: $6,880,613.52, PROTAGONIST THERAPEUTICS INC C
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.60 | $0.13–$3.71 | 519.3% | +10.0% | 6↑ 3↓ | $0.2B | 11 |
| Next Q | $-0.43 | $-0.90–$0.55 | 37.3% | -453.2% | 4↑ 4↓ | $0.0B | 10 |
| Current FY | $4.79 | $3.52–$6.00 | 333.8% | +7.3% | 9↑ 3↓ | $0.5B | 12 |
| Next FY | $-0.20 | $-2.80–$4.75 | -104.2% | -5.7% | 7↑ 4↓ | $0.2B | 12 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.600 | — |
| 7d ago | $2.486 | +0.114 |
| 30d ago | $2.363 | +0.237 |
| 60d ago | $2.235 | +0.364 |
| 90d ago | $2.235 | +0.364 |
Institutional ownership
Which big funds own PTGX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $7.6B total value (62,360,484 shares) as of 2026-Q2. Top holders: NOMURA, BlackRock,, FARALLON. Net buying activity: 33 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 10,307,837 | $1.3B | 16.5% | — |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 6,348,906 | $778.2M | 10.2% | — |
| RTW INVESTMENTS, LP | 5,061,175 | $620.4M | 8.1% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3,629,298 | $444.9M | 5.8% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 3,416,781 | $418.8M | 5.5% | — |
| UBS Group AG | 3,399,221 | $416.7M | 5.5% | TRIM -34.4% |
| STATE STREET CORP | 3,321,554 | $407.2M | 5.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,853,394 | $349.8M | 4.6% | — |
| Invesco Ltd. | 2,340,667 | $286.9M | 3.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| UBS Group AG | TRIM | 5,177,796 | 3,399,221 | -34.4% | $416.7M |
| Alyeska Investment Group, L.P. | ADD | 593,197 | 889,298 | +49.9% | $109.0M |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 454,383 | 571,618 | +25.8% | $70.1M |
| Neuberger Berman Group LLC | DOUBLED | 141,441 | 302,427 | +113.8% | $37.1M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 194,530 | 301,472 | +55.0% | $37.0M |
| Nuveen, LLC | DOUBLED | 127,914 | 284,085 | +122.1% | $34.8M |
| CITIGROUP INC | ADD | 158,711 | 198,668 | +25.2% | $24.4M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 508,103 | 178,152 | -64.9% | $21.8M |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | NEW | — | 141,081 | — | $17.3M |
| TD ASSET MANAGEMENT INC | TRIM | 183,700 | 134,950 | -26.5% | $16.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 44 transactions. Net -$71.1M — $0.00 bought, $71.1M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | PATEL DINESH V PH D | President and CEO | EXERCISE | 7,278 | $21.58 | $157.1K |
| Sep 10, 2026 | PATEL DINESH V PH D | President and CEO | SELL | 7,278 | $144.10 | $1.0M |
| Sep 9, 2026 | PATEL DINESH V PH D | President and CEO | EXERCISE | 63,548 | $21.58 | $1.4M |
| Sep 9, 2026 | PATEL DINESH V PH D | President and CEO | SELL | 63,548 | $146.18 | $9.3M |
| Sep 8, 2026 | PATEL DINESH V PH D | President and CEO | EXERCISE | 54,174 | $21.58 | $1.2M |
| Sep 8, 2026 | PATEL DINESH V PH D | President and CEO | SELL | 54,174 | $145.87 | $7.9M |
| Sep 3, 2026 | PATEL DINESH V PH D | President and CEO | GIFT | 510 | — | — |
| Aug 11, 2026 | PATEL DINESH V PH D | President and CEO | SELL | 34,239 | $148.52 | $5.1M |
| Aug 11, 2026 | PATEL DINESH V PH D | President and CEO | EXERCISE | 34,239 | $21.58 | $738.9K |
| Aug 10, 2026 | PATEL DINESH V PH D | President and CEO | EXERCISE | 65,761 | $21.58 | $1.4M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PTGX.
Shares short
8,140,194
Settlement Sep 15, 2026
Change vs prior
+5.5%
Semi-monthly cycle
Days to cover
15.1
At avg daily volume
Of shares outstanding
≈12.6%
Estimate — not % of float
All PTGX filing & press-release reports (8)
- 144 reportAug 11, 2026
- 8-K reportJun 19, 2026
- INST-CLUSTER reportJun 12, 2026
- CLUSTER reportMay 15, 2026
- CLUSTER reportMay 12, 2026
- 144 reportMay 12, 2026
- 8-K reportMay 5, 2026
- 8-K reportFeb 26, 2026